Plain-English translation of NCT06030076 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is following people with moderate to severe plaque psoriasis who are already planning to switch from their current biologic medication to as part of their regular medical care. Researchers want to understand how the medication works for you and how it affects your quality of life, skin improvement, and overall well-being over about 6 months.
Some people with psoriasis don't respond well to their current biologic treatment, or they experience side effects or dosing challenges. This study aims to understand how well this medication works in real-world practice and whether it improves outcomes for people making the switch.
You likely qualify if…
You likely don't qualify if…
You will visit your dermatologist or psoriasis clinic for regular appointments over about 6 months as you start the new medication. At these visits, your doctor will check how your skin is responding and ask you questions about how you're feeling, your symptoms, and your quality of life. You'll share your experiences with the medication so researchers can understand real-world outcomes — no extra tests or procedures beyond your normal care are required.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Austria
Sponsor
Almirall, S.A.
Enrollment target
~50 participants
Started
September 2023
Primary completion
October 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Senior Director Regional Medical Affairs
Almirall, S.A.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.